ERBB2 and cancer: Nevertheless, the seemingly unavoidable resistance to the therapeutic agents against ErbB2 was acquired by cancer cells in most cases through diverse mechanisms, which include mutations occurring in ErbB2 that abrogate antibody or inhibitor binding [6–8].